All In Biotech

Drug Trial Radar · NCT06773364

Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial

An Investigator Initiated and Conducted, Prospective, Multicentre, Randomised Outcome-blinded Study of Pre-hospital Initiated Levetiracetam and Headposition in Patients With Presumed Acute Stroke

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,423 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,423

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Shanghai East HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. EAST aims to evaluate the effects of pre-hospital levetiracetam and different head positions initiated in ambulance settings on the functional outcome of participants assessed at 90 days.

Conditions

  • Suspected Stroke

Interventions

  • LevetiracetamDrug

    Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH

  • Guide-recommended managementOther

    To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.

  • The lying flat (0°) head positionOther

    Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.

  • The sitting-up (≥30°) head positionOther

    Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional shift (improvement) in 7-level mRS scoresTime frame: 90 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Si County People's Hospital

    Suzhou, Anhui, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.